demo

Prof Wang was invited to attend Tigermed’s ASCO Pre-Event Webinar as a Speaker to introduce Qurgen’s breakthrough cell converting cancer

no infusion related reaction (IRR) has occurred during the 48-hour continuous infusion by pump, this indicates a significantly enhanced safety

Qurgen has completed SON-DP treatment for multiple late-stage solid tumor patients for over 18-months at low dose levels (2-4.5 mg/kg)

Qurgen expanded 4 additional hospitals (Sarah Cannon Research Institute Tennessee, HCA HealthONE Denver, California Research Institute, LLC, Allison, Curtis, Kingsley,